Literature DB >> 21329686

Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK.

Polychronis Pavlidis, Alastair Forbes, Dimitrios P Bogdanos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21329686     DOI： 10.1016/j.cca.2011.02.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


× No keyword cloud information.
  9 in total

1.  Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.

Authors:  Frauke Degenhardt; Andrea Dirmeier; Rocio Lopez; Sylvia Lang; Claudia Kunst; Dirk Roggenbuck; Dirk Reinhold; Silke Szymczak; Gerhard Rogler; Frank Klebl; Andre Franke; Florian Rieder
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

2.  Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.

Authors:  Ali Erkan Duman; Sadettin Hülagü; Altay Çelebi; Uğur Korkmaz; Mahmut Mert Musul; Ömer Şentürk; Göktuğ Şirin; Hasan Yılmaz; Deniz Öğütmen Koç; Gökhan Dindar; Murat Öztürkler; Neslihan Bozkurt; Hale Maral Kır
Journal:  Turk J Gastroenterol       Date:  2019-01       Impact factor: 1.852

3.  Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.

Authors:  Shulan Zhang; Jing Luo; Ziyan Wu; Dirk Roggenbuck; Peter Schierack; Dirk Reinhold; Ji Li; Xiaofeng Zeng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Clin Transl Gastroenterol       Date:  2018-02-15       Impact factor: 4.488

4.  Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.

Authors:  Martin W Laass; Nadja Röber; Ursula Range; Lydia Noß; Dirk Roggenbuck; Karsten Conrad
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 5.  Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis.

Authors:  Chuiwen Deng; Wenli Li; Jing Li; Shulan Zhang; Yongzhe Li
Journal:  BMJ Open       Date:  2017-06-09       Impact factor: 2.692

6.  Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.

Authors:  Polychronis Pavlidis; Ourania Romanidou; Dirk Roggenbuck; Maria G Mytilinaiou; Faris Al-Sulttan; Christos Liaskos; Daniel S Smyk; Andreas L Koutsoumpas; Eirini I Rigopoulou; Karsten Conrad; Alastair Forbes; Dimitrios P Bogdanos
Journal:  Clin Dev Immunol       Date:  2012-10-17

7.  Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.

Authors:  Dimitrios P Bogdanos; Dirk Roggenbuck; Dirk Reinhold; Thomas Wex; Polychronis Pavlidis; Ulrike von Arnim; Peter Malfertheiner; Alastair Forbes; Karsten Conrad; Martin W Laass
Journal:  BMC Gastroenterol       Date:  2012-08-06       Impact factor: 3.067

Review 8.  CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.

Authors:  Christos Liaskos; Eirini I Rigopoulou; Timoklia Orfanidou; Dimitrios P Bogdanos; Christos N Papandreou
Journal:  Clin Dev Immunol       Date:  2013-04-22

9.  Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.

Authors:  Shulan Zhang; Ziyan Wu; Jing Luo; Xuefeng Ding; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.